Injection site reactions Redness, mild swelling, itching, or a small bump at the injection site are common and usually resolve within 24-48 hours
Briefly, insect cells were grown in ESF 921 culture medium (Expression Systems) to a density of 3.2 10 6 cells/mL
Based on general principles applicable to subcutaneous injectable therapies: Those who do not rotate injection sites adequately , leading to repeated trauma to the same area Individuals on concomitant anticoagulant therapy (for example, warfarin or direct oral anticoagulants), who may experience more pronounced bruising People with a history of allergic skin conditions , who may be more prone to localised irritation, though this has not been specifically studied for retatrutide It should be noted that risk factors relating to specific excipients or the effect of body mass index on injection site reactions cannot be confirmed at this stage, as retatrutide's final formulation details are not yet publicly available in a licensed SmPC
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists